一项研究表明,Dostarlimab是一种免疫疗法药物,可以消除一些早期癌症病人的手术需求。 A study shows dostarlimab, an immunotherapy drug, may eliminate surgery needs for some early-stage cancer patients.

新英格兰医学杂志的一项新研究表明,免疫疗法药物Dostarlimab可能有助于一些早期癌症患者避免外科手术。 A new study in the New England Journal of Medicine suggests that the immunotherapy drug dostarlimab may help some patients with early-stage cancers avoid surgery. 在103名参加者中,82人对药物反应良好,不再需要手术。 Out of 103 participants, 82 responded well to the drug, no longer needing an operation. 这项研究的重点是特定基因改变的病人,影响约2-3%的癌症病人。 The study focused on patients with a specific genetic alteration, which affects about 2-3% of cancer patients. 研究人员希望将这一方法扩大到更多类型的癌症。 Researchers hope to expand this approach to more types of cancer.